Acadian Asset Management’s Sarepta Therapeutics SRPT Stock Holding History

Acadian Asset Management’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.06M	Sell	58,935 -40,174	-41%	-$760K	﹤0.01%	1247
2026 Q1	$2.15M	Buy	99,109 +5,610	+6%	+$109K	﹤0.01%	936
2025 Q4	$2.01M	Buy	93,499 +68,197	+270%	+$1.44M	﹤0.01%	910
2025 Q3	$483K	Buy	+25,302	New	+$451K	﹤0.01%	1231
2024 Q3	–	Sell	-8,566	Closed	-$1.35M	–	2320
2024 Q2	$1.35M	Buy	+8,566	New	+$1.1M	﹤0.01%	894
2024 Q1	–	Sell	-1,879	Closed	-$180K	–	1774
2023 Q4	$180K	Buy	+1,879	New	+$180K	﹤0.01%	1252
2023 Q3	–	Sell	-498	Closed	-$57K	–	1832
2023 Q2	$57K	Sell	498 -494	-50%	-$63.7K	﹤0.01%	1509
2023 Q1	$136K	Buy	992 +100	+11%	+$13K	﹤0.01%	1336
2022 Q4	$115K	Sell	892 -4,384	-83%	-$508K	﹤0.01%	1405
2022 Q3	$581K	Buy	5,276 +2,271	+76%	+$229K	﹤0.01%	951
2022 Q2	$224K	Buy	+3,005	New	+$221K	﹤0.01%	1172
2022 Q1	–	Sell	-5,683	Closed	-$510K	–	1788
2021 Q4	$510K	Sell	5,683 -1,001	-15%	-$85.6K	﹤0.01%	1006
2021 Q3	$617K	Buy	+6,684	New	+$515K	﹤0.01%	983
2021 Q2	–	Sell	-3,819	Closed	-$285K	–	2197
2021 Q1	$285K	Buy	+3,819	New	+$352K	﹤0.01%	1382
2020 Q3	–	Sell	-173	Closed	-$28K	–	2347
2020 Q2	$28K	Buy	+173	New	+$23.5K	﹤0.01%	2065

Other funds holding SRPT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Acadian Asset Management's SRPT Position: Q2 2026 in Review

Acadian Asset Management reduced its Sarepta Therapeutics (SRPT) stake by 41% in Q2 2026, selling an estimated $760K and leaving 58,935 shares worth $1.06M. The position accounts for ﹤0.01% of the portfolio, ranked #1247.

Acadian Asset Management first reported a position in SRPT in Q2 2020 and has held it in 15 quarters since. The position peaked at $2.15M in Q1 2026. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

Acadian Asset Management held 58,935 shares of Sarepta Therapeutics worth $1.06M as of Q2 2026.
Acadian Asset Management sold 40,174 Sarepta Therapeutics shares in Q2 2026, an estimated $760K.
Sarepta Therapeutics made up ﹤0.01% of Acadian Asset Management's portfolio in Q2 2026, its #1247 holding.
Acadian Asset Management first reported a position in Sarepta Therapeutics in Q2 2020 and has held it in 15 quarters since.
Acadian Asset Management's Sarepta Therapeutics position peaked at $2.15M in Q1 2026.
323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.